5FU-related MI, and one patient with bowel perforation. No treatment related deaths occurred. Patients older than 70 had a lower completion rate (28.5% vs. 77%, p ¼ 0.016), higher admission rate (85% vs. 61%, p ¼ 0.228) but similar grade 3/4 toxicity rate (57% vs. 61%, p ¼ 0.832) compared to younger counterparts. Compared to AIO -FLOT4 trial, our patients had higher rates of: discontinuation (33.3% vs. 6%), dose reductions (24% vs. 6%) and serious adverse events (70% vs. 41%). The commonest grade3/4 toxicity was neutropenia in both cohorts, but was less frequent in our institution (30% vs. 52%) probably due to primary GCSF prophylaxis. Grade 3/4 nausea/ vomiting was commonest in the AOI-FLOT 4 cohort (12% vs. 6%), while grade3/4 diarrhoea was more frequent in our institution (12% vs. 7%). Fatigue grade 3/4 was commonest in our cohort (12% vs. 9%). No grade 3/4 cases of neurotoxicity were reported in our cohort, compared with the AIO-FLOT4 (8%). Conclusion: Neoadjuvant FLOT for resectable GOA was less tolerable and more toxic in our cohort, with higher rate of early treatment discontinuations, dose reductions, serious adverse events. The above results demonstrate that every day clinical practice often differs from trial results and underscore the importance of reporting real world experience data, especially regarding safety issues.

Conclusion: Overall, Our findings suggest that catechin hydrate inhibits B(a)P-induced lung tumor formation by modulating hyperproliferation, inflammation, apoptosis and ALDH1 expression.